Availability of Implantable System for Remodulin Likely Late 2019

2018-09-14T20:49:14+00:00 September 14th, 2018|

The Food and Drug Administration (FDA) recently approved the Implantable System for Remodulin® (ISR), a collaboration between United Therapeutics Corporation and Medtronic. The ISR is approved for adults with functional class I, II and III pulmonary arterial hypertension (PAH) who are receiving intravenous (IV) treprostinil therapy. There are a very limited number of ISRs currently

Navigating Access to Generic Therapy

2018-09-14T20:44:07+00:00 September 14th, 2018|

The Pulmonary Hypertension Association (PHA) reported Aug. 17 that generic tadalafil was approved by the Food and Drug Administration (FDA) and suggested that pulmonary hypertension (PH) patients taking Adcirca® discuss the implications with their care teams. Since then, generic tadalafil has become available through many health insurance plans. In addition, PHA has been advised

Treating PH: Joint Symposium Discusses Options

2018-09-07T20:04:55+00:00 September 7th, 2018|

by Phyllis Hanlon, Contributing Writer Although there are 14 different Food and Drug Administration (FDA)-approved therapies for treating World Health Organization (WHO) Group 1 pulmonary hypertension (PH) (pulmonary arterial hypertension, or PAH), there remains a need for treatments that can be used across varying classifications of PH. In 2017, the Critical Care Medicine Department of

Share Your Oxygen Experiences: PHA Responds to Proposed Changes to Medicare Oxygen Coverage

2018-09-07T20:07:48+00:00 September 7th, 2018|

The Centers for Medicare and Medicaid Services (CMS) has proposed significant changes to how home oxygen (also known as supplemental oxygen) is regulated and paid for. The Pulmonary Hypertension Association (PHA) is taking action to improve the pulmonary hypertension (PH) community’s experience accessing home oxygen. If you have been prescribed home oxygen, you can help

Examination of PHAR Data Shows Few Patients are Referred to Palliative Care

2018-08-31T15:42:34+00:00 August 31st, 2018|

Although treatment options for WHO Group 1 PH (pulmonary arterial hypertension, or PAH) have increased over the past few decades, symptom severity and quality of life still impose significant burden on patients. Palliative care – often confused with hospice care – is goal-oriented care for patients with chronic illnesses that help to balance life-saving

FDA Approves Generic Version of Adcirca®; Additional Approvals May Come Soon

2018-08-21T13:45:25+00:00 August 17th, 2018|

The Pulmonary Hypertension Association (PHA) recently learned that the Food and Drug Administration (FDA) has approved a generic version of tadalafil, the pulmonary arterial hypertension (PAH)-targeted therapy sold as Adcirca®. Availability of the generic therapy for patients remains to-be-determined. PHA also has been advised that generic versions of other PAH-targeted therapies may become available soon.

Latest PH Roundtable Focuses on Palliative Care, the Misconceptions and Benefits

2018-08-17T21:44:59+00:00 August 17th, 2018|

The latest issue of Advances in Pulmonary Hypertension focuses on palliative care as an integral component of treating people with pulmonary hypertension (PH). Many people have the misconception that palliative care relates solely to hospice care, which is end of life care and only one part of palliative care. Palliative care, named from the

Learning to Live Your Best Life: Join PHA on the Road in 2018

2018-08-03T21:26:13+00:00 August 3rd, 2018|

The Pulmonary Hypertension Association (PHA) announces the dates and cities for two PHA on the Road: PH Patients and Families Education Forums for 2018. Forums are scheduled in Long Beach, Calif., September 29, and Milwaukee, October 27. PHA on the Road, a program of the PHA Medical Education Fund,* provides a unique opportunity for

United Therapeutics Receives FDA Approval for the Implantable System for Remodulin®

2018-08-03T21:23:00+00:00 August 3rd, 2018|

United Therapeutics Corporation announced July 31 that it had received approval from the Food and Drug Administration (FDA) for Remodulin® (treprostinil) to be used in the Implantable System for Remodulin® for patients with WHO Group 1 PH (pulmonary arterial hypertension, or PAH). Development of the Implantable System for Remodulin® resulted from a collaboration between United

Participation in PHA Conference Opens Doors for Northwestern University Researcher

2018-07-27T17:41:33+00:00 July 27th, 2018|

Zhiyu Dai, Ph.D., a researcher at Northwestern University and assistant professor of research at Northwestern University Feinberg School of Medicine in Chicago, has presented his work during the past two Pulmonary Hypertension Association (PHA) International PH Conference and Scientific Sessions. He also has been awarded top abstract in basic science by the Scientific Sessions